Asensus Surgical Announces $10 Million Registered Direct Offering
27 Juillet 2023 - 3:01PM
Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus” or the
“Company”), a medical device company that is digitizing the
interface between the surgeon and the patient to pioneer a new era
of Performance-Guided Surgery™, today announced that it has entered
into a definitive agreement for the purchase and sale of an
aggregate of 23,809,524 shares of its common stock and
warrants to purchase 23,809,524 shares of common stock in a
registered direct offering. The shares of common stock and
accompanying warrants are being sold at a combined purchase price
of $0.42 per share and accompanying warrant to purchase one share
of common stock. The warrants have an exercise price of $0.42 per
share, are immediately exercisable and will expire five years
following the date of issuance. The offering is expected to close
on or about July 31, 2023, subject to the satisfaction of customary
closing conditions.
H.C. Wainwright & Co. is acting as the
exclusive placement agent for the offering.
The gross proceeds from the offering to the
Company are expected to be $10 million, before deducting placement
agent’s fees and other offering expense payable by the Company. The
Company intends to use the net proceeds from the offering for
general corporate purposes, including working capital and funding
research and development activities.
A shelf registration statement on Form S-3 (File
No. 333-263711) relating to the securities being offered was filed
with the U.S. Securities and Exchange Commission (the “SEC”) on
March 18, 2022, and became effective on April 28, 2022. The
offering is being made only by means of a prospectus supplement and
accompanying prospectus that form a part of the shelf registration
statement. The final prospectus supplement and accompanying
prospectus relating to the offering will be filed with
the SEC and will be available on the SEC’s website
at www.sec.gov. Electronic copies of the final prospectus
supplement and accompanying prospectus relating to the offering,
when filed, may be obtained on the SEC’s website
at www.sec.gov or by contacting H.C. Wainwright & Co.,
LLC, 430 Park Avenue, New York, NY 10022, by email at
placements@hcwco.com or by phone at (212) 856-5711.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful, prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Asensus Surgical,
Inc.
Asensus Surgical, Inc. is digitizing the
interface between the surgeon and patient to pioneer a new era of
Performance-Guided Surgery by unlocking clinical intelligence for
surgeons to enable consistently superior outcomes and a new
standard of surgery. Based upon the foundations of Digital
Laparoscopy and the Senhance® Surgical System, the Company is
developing the LUNA™ Surgical System, a next generation robotic and
instrument system as a foundation of its Digital Surgery solution.
These systems will be powered by the Intelligent Surgical Unit™ to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, Augmented Intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. The Senhance Surgical System is now available for sale
in the US, EU, Japan, Russia, and select other countries. For a
complete list of indications for use, visit:
www.senhance.com/indications. To learn more about
Performance-Guided Surgery, Digital Laparoscopy with the Senhance
Surgical System and the new LUNA System visit www.asensus.com.
Forward-Looking Statements
This press release includes statements relating
to the offering of our securities. These statements, including,
without limitation, as to the completion of the offering, the
satisfaction of the customary closing conditions of the offering
and the intended use of proceeds from the offering, and other
statements regarding our future plans and goals constitute "forward
looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and are intended to qualify for the safe harbor from
liability established by the Private Securities Litigation Reform
Act of 1995. Such statements are subject to risks and uncertainties
that are often difficult to predict, are beyond our control and
which may cause results to differ materially from expectations and
include market and other conditions. For a discussion of the risks
and uncertainties associated with our business, please review our
filings with the Securities and Exchange Commission (SEC). You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
law.
Contact:
For Asensus Surgical, Inc.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie ICR Westwicke
invest@asensus.com 443-213-0499
MEDIA CONTACT: Dan Ventresca
Matter Communications AsensusPR@matternow.com 617-874-5488
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024